GeneRx Innovations

At GeneRx Innovations, we are on a mission to revolutionize the treatment landscape for rare genetic disorders through groundbreaking gene therapy solutions. Our lead product candidate, GTx-101, targets a specific gene mutation responsible for a debilitating condition affecting children. With initial preclinical studies yielding promising results, the need for funding has never been more critical. This capital will enable us to expand our clinical trials and bring GTx-101 one step closer to market. Over the past year, we successfully completed our FDA pre-IND meeting and have established partnerships with leading research institutions to validate our findings. Our dedicated team of scientists and researchers has made significant progress, and we have secured preliminary funding of $800,000, which has been utilized to support early-stage research and development. The next phase requires a more substantial investment to conduct Phase 1 clinical trials and optimize our drug formulation. We believe that with your investment, we can advance GTx-101 through the next stages of development and fulfill a pressing need in the market. Our goal is to not only provide a therapeutic option for p…

The $1,500,000 investment will primarily be used as follows:

• Clinical Trials: $800,000 for Phase 1 clinical trials, including patient recruitment, site fees, and monitoring expenses.
• Regulatory Compliance: $300,000 to ensure all regulatory requirements are met and to prepare for regulatory submissions.
• R&D Enhancements: $200,000 for advancing our manufacturing capabilities and optimizing the scalability of our gene therapy product.
• Operational Costs: $200,000 for hiring key personnel and administrative costs to support ongoing operations.